What one share of Relay Therapeutics holds
We are a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Our Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed.
Relay Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$1.57 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.17 |
| Cash and investments | $0.55 |
| Book value | $4.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$21.82 | $2.32 | −$21.49 | — | −$44.69 |
| 2020 | $1.94 | −$5.40 | $0.05 | −$2.45 | — | — |
| 2021 | $0.03 | −$3.82 | $0.04 | −$0.82 | — | $8.30 |
| 2022 | $0.01 | −$2.59 | $0.08 | −$2.13 | — | $7.85 |
| 2023 | $0.21 | −$2.79 | $0.03 | −$2.48 | — | $5.90 |
| 2024 | $0.07 | −$2.36 | $0.01 | −$1.76 | — | $4.64 |
| 2025 | $0.09 | −$1.61 | $0.00 | −$1.37 | — | $3.26 |
Common questions about Relay Therapeutics
How much does one share of Relay Therapeutics earn?
Over the last 12 months, Relay Therapeutics lost $1.57 for each share on $0.06 of sales.
Does Relay Therapeutics pay a dividend?
Relay Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Relay Therapeutics’s book value per share?
Relay Therapeutics’s book value is $4.07 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Relay Therapeutics have?
Each share of Relay Therapeutics has $0.55 of cash and investments, as of June 30, 2026.
What is Relay Therapeutics’s free cash flow per share?
−$1.17 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Relay Therapeutics bought back shares?
Relay Therapeutics’s share count rose about 4873% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.